vaccines

an Open Access Journal by MDPI

IMPACT FACTOR 3.4

Indexed in: PubMed

CITESCORE 7.7

DNA Vaccine Development and Delivery Methods: Current Status and Future Perspective

Guest Editor:

Dr. Muthu Narayanan
Masonic Medical Research Institute, Utica, NY 13501, USA

Deadline for manuscript submissions:
closed (31 December 2021)

Message from the Guest Editor

Genetic vaccines use one or more of the genes of the virus to activate the host immune response. DNA vaccines instigate cell-mediated immunity, which is effective against many pathogens, compared to standard vaccines that fail to work. A pathogenic epitope is expressed in the host after DNA vaccination, which makes it more effective than the standard vaccine. Moreover, the antigenicity is altered in the manufacturing process of the live attenuated or killed vaccine, which is not observed in the DNA vaccines. The process of construction and manufacturing is very simple with DNA vaccines.

Vaccination for many communicable (including Covid-19) and non-communicable diseases (cancer, atherosclerosis) is still a distant dream in both developed and developing countries. This Special Issue will focus on DNA vaccine development and delivery methods for communicable and non-communicable diseases. Research articles, review articles, and short communication based on the current status and future perspectives of the DNA vaccination development are invited.

vaccines

IMPACT FACTOR 3.4 | Indexed in: PubMed | CITESCORE 7.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
𝕏@Vaccines_MDPI